Drug Maker Teva Pharmaceuticals Agrees To Pay $450M In False Claims Act Settlement To Resolve Kickback Allegations Relating To Copayments And Price Fixing
Teva Pharmaceuticals USA Inc. (Teva USA) and Teva Neuroscience Inc. (collectively, Teva) have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). Teva, headquartered in Parsippany, New Jersey, is the largest generic drug manufacturer in the United States. The settlement amount was based on Teva’s ability to pay.
Action Details
- Date:October 10, 2024
- Agency:U.S. Department of Justice
-
Enforcement Types:
- Criminal and Civil Actions